Latest news
Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial - BioPharma APACBioPharma APAC · Thu, 06 Aug 2026 01:05:52 GMTForlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia - Business WireBusiness Wire · Tue, 04 Aug 2026 12:00:00 GMT